GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biocartis Group NV (CHIX:BCARTb) » Definitions » Median PS Value

Biocartis Group NV (CHIX:BCARTB) Median PS Value : €0.00 (As of Jun. 19, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Biocartis Group NV Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Biocartis Group NV's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was €0.806. Biocartis Group NV's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is €0.00.

As of today (2025-06-19), Biocartis Group NV's share price is €1.36345. Biocartis Group NV's Median PS Value is €0.00. Therefore, Biocartis Group NV's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for Biocartis Group NV's Median PS Value or its related term are showing as below:

CHIX:BCARTb's Price-to-Median-PS-Value is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 0.84
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

Biocartis Group NV Median PS Value Historical Data

The historical data trend for Biocartis Group NV's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocartis Group NV Median PS Value Chart

Biocartis Group NV Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Median PS Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Biocartis Group NV Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Biocartis Group NV's Median PS Value

For the Diagnostics & Research subindustry, Biocartis Group NV's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biocartis Group NV's Price-to-Median-PS-Value Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biocartis Group NV's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Biocartis Group NV's Price-to-Median-PS-Value falls into.


;
;

Biocartis Group NV Median PS Value Calculation

Biocartis Group NV's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=0.806*0
=0.00

10-Year Median PS Ratio is 0.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Biocartis Group NV's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was €0.806.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biocartis Group NV  (CHIX:BCARTb) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Biocartis Group NV's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=1.36345/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biocartis Group NV Median PS Value Related Terms

Thank you for viewing the detailed overview of Biocartis Group NV's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Biocartis Group NV Business Description

Traded in Other Exchanges
N/A
Address
Generaal de Wittelaan 11 B, Mechelen, BEL, 2800
Biocartis Group NV is a commercial-stage molecular diagnostics company. It provides diagnostic solutions aimed at improving clinical practice for patients, clinicians, payers, and the industry. The firm has developed an MDx Idylla molecular diagnostic system for oncology and infectious disease segments. Its products include EGFR mutation assay, BRAF mutation test, NRAS mutation test, respiratory panel, etc. The firm derives the majority of its revenues from product sales.

Biocartis Group NV Headlines

No Headlines